AgelessRx has launched oral sublingual drops for the GLP-1 receptor agonists Semaglutide and Tirzepatide, offering a non-injectable alternative for metabolic health management. This move aims to broaden access to therapies that may combat age-related decline and promote longevity. The company believes GLP-1s are crucial for overall health and healthspan due to their potential impact on metabolic function.

This development is important because it addresses a significant barrier to access for individuals seeking the potential benefits of GLP-1 therapies. Injectable medications can be inconvenient and deter some patients. The oral sublingual delivery method may improve patient compliance and expand the reach of these treatments to a wider population, including those who may have previously been hesitant due to the need for injections. This could significantly impact the adoption of GLP-1s for metabolic health and longevity purposes.

AgelessRx’s sublingual drops utilize a SubMagna SL HMW compound for faster absorption into the bloodstream. The company’s approach emphasizes preventative care and personalized treatment, aligning with core principles of longevity science. Their Stanford PhD-led Applied Sciences team is also researching broader applications of GLP-1s in extending lifespan.

This launch positions AgelessRx as an innovator in the longevity field. Providing accessible and convenient GLP-1 treatments could accelerate the mainstream adoption of longevity-focused therapies. This could further drive research and development in the field and potentially transform how we approach age-related health management in the future.

Source link: http://www.businesswire.com/news/home/20250205804927/en/AgelessRx-Expands-Offerings-to-Include-Oral-GLP-1-Drops-to-Advance-Metabolic-Health-and-Longevity-Science

+ posts

Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.